DGAP-News: MOLOGEN AG: Court appoints new Supervisory Board member

PRESS RELEASE N 10 / 2019 of 21/06/2019

MOLOGEN AG: Court appoints new Supervisory Board member

Berlin, 21 June 2019 - Using the application procedure pursued by MOLOGEN AG (ISIN DE000A2LQ900 / SIN A2LQ90), the District Court at Charlottenburg, Berlin, has legally appointed attorney Gerhard Greif as new member of the Supervisory Board of MOLOGEN AG with effect from 17 June 2019 up until the conclusion of the Annual General Meeting on 22 August 2019. In the past, Gerhard Greif has advised the Company in various areas, particularly with regard to approaching investors and capital market funding. With this appointment, the Supervisory Board of the Company is once again complete. The position on the Supervisory Board had become vacant following the resignation on 30 April 2019 of Dr med Stefan M. Manth from the position of Deputy Chairman of the Supervisory Board of MOLOGEN AG in order to assume the vacant role of Chief Executive Officer on 1 May 2019.

MOLOGEN AG
MOLOGEN AG is a biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.

The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM(R).

The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in extensive-stage small cell lung cancer (ES-SCLC) and the data from the extension phase of the TEACH study in HIV have been published.
In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy^(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.

MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.

MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN DE000A2LQ900 / SIN A2L Q90) are listed in the Prime Standard of the German Stock Exchange.

www.mologen.com

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 37
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.